Description: Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
Home Page: www.spyre.com
221 Crescent Street
Waltham,
MA
02453
United States
Phone:
617 651 5940
Officers
| Name | Title |
|---|---|
| Dr. Cameron Turtle DPHIL, Ph.D. | CEO & Director |
| Mr. Scott L. Burrows | Chief Financial Officer |
| Ms. Heidy Abreu King-Jones J.D., L.L.M. | Chief Legal Officer & Corporate Secretary |
| Dr. Janet Gunzner-Toste M.B.A., Ph.D. | Senior Vice President of Operations |
| Mr. Brian Connolly | Chief Technical Officer |
| Mr. Eric McIntyre | Vice President of Finance & Investor Relations |
| Mr. James Myers | Vice President of Quality & Compliance |
| Dr. Kelly Boothe Ph.D. | Senior Director of Corporate Communications & Investor Relations |
| Dr. Justin LaFountaine Ph.D. | Senior Vice President of Corporate Development |
| Ms. Melissa Cooper | Senior Vice President of People |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 8.1847 |
| Price-to-Sales TTM: | 2209.9204 |
| IPO Date: | 2016-04-07 |
| Fiscal Year End: | December |
| Full Time Employees: | 30 |